ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "radiography and rheumatoid arthritis (RA)"

  • Abstract Number: 1957 • 2013 ACR/ARHP Annual Meeting

    Correlation Of Structural Abnormalities Of The Wrist and Metacarpophalangeal Joints Evaluated By High-Resolution Peripheral Quantitative Computed Tomography, 3 Tesla MRI and Conventional Radiographs In Rheumatoid Arthritis

    Chan Hee Lee1,2, Waraporn Srikhum2,3, Andrew J. Burghardt4, Warapat Virayavanich2,5, Thomas M. Link2, John B. Imboden6 and Xiaojuan Li7, 1Div Rheum Dept of Intl Med, NHIC Ilsan Hospital, Goyang-si, South Korea, 2Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, 3Department of Radiology, Thammasat University, Pathumthani, Thailand, 4Department of Radiology & Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA, 5Department of Radiology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, 6Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA, 7Department of Radiology and Biomedical Imaging, Musculoskeletal Quantitative Imaging Research, UCSF, San Francisco, CA

    Background/Purpose: Early detection of joint inflammation and tissue damage are critical for patient management in rheumatoid arthritis (RA). High-resolution peripheral quantitative computed tomography (HR-pQCT) is…
  • Abstract Number: 1968 • 2013 ACR/ARHP Annual Meeting

    A Novel, Feasible and Reliable Method Of Radiographic Scoring Of Rheumatoid Arthritis

    Priyanka Vashisht1, Harlan Sayles2, Ted R. Mikuls2 and Alan R. Erickson2, 1Creighton University Medical Center, Omaha, NE, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Radiographs of the hands and feet are used to evaluate the disease course of rheumatoid arthritis (RA) with several scoring systems previously described. However,…
  • Abstract Number: 1457 • 2013 ACR/ARHP Annual Meeting

    Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice

    Isao Matsushita1, Hiraku Motomura1, Eiko Seki1 and Tomoatsu Kimura2, 1Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, 2Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan

    Background/Purpose: Abatacept is approved for use with or without methotrexate (MTX). The purpose of this study was to clarify the inhibitory effect of abatacept on…
  • Abstract Number: 1464 • 2013 ACR/ARHP Annual Meeting

    Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)

    Boulos Haraoui1, J. Carter Thorne2, Edward C. Keystone3, Melanie Poulin-Costello4, Eric Trottier5, Andrew Vieira6 and Janet E. Pope7, 1Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, 2Southlake Regional Health Centre, Newmarket, ON, Canada, 3Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, 4Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, 5Medical Communications, Amgen Canada, Mississauga, ON, Canada, 6Amgen Canada Inc., Mississauga, ON, Canada, 7St Joseph Health Care, London, ON, Canada

    Background/Purpose: Data from the CAMEO study demonstrated that patients with rheumatoid arthritis (RA) who achieved low disease activity (LDA) after 6 months of combination therapy…
  • Abstract Number: 1304 • 2013 ACR/ARHP Annual Meeting

    Anti-Carbamylated Antibody Positivity Is Associated With More Severe Radiological Progression In Patients With Recent Onset ACPA Negative Rheumatoid Arthritis: Results From The Norfolk Arthritis Register (NOAR)

    Jenny H. Humphreys1, Suzanne M. Verstappen1, Kimme L. Hyrich2, Tarnya Marshall3, Anne Barton4,5, René E.M. Toes6, Leendert A. Trouw6 and Deborah P. Symmons4,7, 1Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 3Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, 4Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 5NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom

    Background/Purpose: Autoantibodies against carbamylated proteins (anti-CarP) have been associated with more severe radiological damage in patients with rheumatoid arthritis (RA), including in a small subgroup…
  • Abstract Number: 1305 • 2013 ACR/ARHP Annual Meeting

    Clinical Joint Involvement Is Decisive For Radiographic Progression

    Miriam Gärtner1, Farideh Alasti2, Gabriela Supp1, Josef S. Smolen3 and Daniel Aletaha1, 1Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 3Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria

    Background/Purpose: Today’s therapeutic targets in rheumatoid arthritis (RA) are remission or low disease activity, but it was shown that joint damage may continue to progress…
  • Abstract Number: 1310 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of The Japanese Patients With Rheumatoid Arthritis (RA) Of Rapid Radiographic Progression (RRP) Treated With Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) In Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (an interim report of Apple Survey)

    Akitomo Okada1, Atsushi Kawakami2, Takaaki Fukuda3, Toshihiko Hidaka4, Tomonori Ishii5, Yukitaka Ueki6, Takao Kodera7, Munetoshi Nakashima1, Yuichi Takahashi8, Seiyo Honda9, Yoshiro Horai2, Tomohiro Koga10, Mami Tamai11, Kiyoshi Aoyagi12, Ryu Watanabe5, Hiroshi Okuno13 and Katsumi Eguchi14, 1Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, 4Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, 5Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 6Sasebo Chuo Hospital, Sasebo, Japan, 7Tohoku Kosei Nenkin Hospital, Sendai, Japan, 8Yu Family Clinic, Sendai, Japan, 9Kurume University School of Medicene, Kurume, Japan, 10Departments of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 11Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, 12Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 13Tohoku University Hospital, Sendai, Japan, 14Sasebo City General Hospital, Sasebo, Nagasaki, Japan

    Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) are known to inhibit radiographic progression in patients with rheumatoid arthritis (RA). However, there has been few epidemiological report…
  • Abstract Number: 1012 • 2012 ACR/ARHP Annual Meeting

    Radiographic Deformity of the Foot Is Starting From the Early Stage of Rheumatoid Arthritis

    Kenji Mamoto1, Tatsuya Koike2, Tadashi Okano1, Atsuko Kamiyama2, Yuko Sugioka1, Masahiro Tada1 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: Foot deformities frequently arise in patients with rheumatoid arthritis (RA). It might cause gait dysfunction and lead to disability. However, the precise mechanism of…
  • Abstract Number: 981 • 2012 ACR/ARHP Annual Meeting

    Aggregated Genetic Information Explains Variations On Hand Radiographic Scores in Rheumatoid Arthritis Patient

    Jing Cui1, Nancy A. Shadick2, Katherine P. Liao3, Michael Weinblatt4, Robert M. Plenge5 and Elizabeth W. Karlson3, 1Rheumatology, Brigham and Women's Hospital, Boston, MA, 2Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 5Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) has an estimated heritability of approximately 60%. Joint destruction as a severity measure of RA is influenced by genetic factors, however…
  • Abstract Number: 812 • 2012 ACR/ARHP Annual Meeting

    Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial

    Michael Weinblatt1, Clifton O. Bingham III2, Alan Mendelsohn3, Lenore Noonan4, Shihong Sheng5, Lilianne Kim6, Kim Hung6, Jiandong Lu6, Daniel Baker6 and Rene Westhovens7, 1Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 2Department of Medicine, Johns Hopkins University, Baltimore, MD, 3Immunology, Janssen Research & Development, LLC, Spring House, PA, 4Immunology, Janssen Research & Development, LLC., Spring House, PA, 5Biostatistics, Janssen Research & Development, LLC, Spring House, PA, 6Janssen Research & Development, LLC, Spring House, PA, 7Rheumatology, University Hospital KU Leuven, Leuven, Belgium

    Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: 1-Year Results of a Phase…
  • Abstract Number: 766 • 2012 ACR/ARHP Annual Meeting

    Anemia May Provide Clinically Relevant Information Beyond Conventional Disease Activity Assessment to Predict Radiographic Damage Progression in Rheumatoid Arthritis

    Burkhard Moller1, Frauke Förger2, Peter M. Villiger3 and Axel Finckh4, 1Rheumatology, Inselspital University Hospital, Bern, Switzerland, 2Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, 3Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, 4Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland

    Anemia may provide clinically relevant information beyond conventional disease activity assessment to predict radiographic damage progression in Rheumatoid ArthritisBurkhard Möller, Frauke Förger, Peter M. Villiger,…
  • Abstract Number: 2142 • 2012 ACR/ARHP Annual Meeting

    Magnetic Resonance Imaging-Proven Osteitis At Baseline Predicts the Early Rheumatoid Arthritis Patients Who Will Develop Rapid Radiographic Progression: MRI Is Beneficial to Find the Window of Opportunity in Early RA

    Mami Tamai1, Yoshikazu Nakashima2, Takahisa Suzuki3, Yoshiro Horai2, Akitomo Okada4, Junko Kita4, Shin-ya Kawashiri2, Naoki Iwamoto4, Kunihiro Ichinose5, Kazuhiko Arima4, Hideki Nakamura1, Tomoki Origuchi6, Masataka Uetani7, Kiyoshi Aoyagi8, Katsumi Eguchi9 and Atsushi Kawakami2, 1Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 6Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 7Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 8Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 9Sasebo City General Hospital, Sasebo, Nagasaki, Japan

    Background/Purpose: Window of opportunity exists in the earlier phase of rheumatoid arthritis (RA), thus, early recognition of the RA patients who will develop rapid radiographic…
  • Abstract Number: 770 • 2012 ACR/ARHP Annual Meeting

    Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct Entity of RA? Results From the Swiss Observational Cohort

    Ruediger Mueller1, Toni Kaegi1, Axel Finckh2 and Johannes von Kempis1, 1Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 2Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland

    Background/Purpose: Rheumatoid arthritis (RA) is generally described as a disease with two peaks of onset, either late (late onset RA, LORA) or early (young onset…
  • Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting

    Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis

    Josef S. Smolen1, Ronald F. van Vollenhoven2, Andrew S. Koenig3, Ronald Pedersen3, Annette Szumski4 and Eustratios Bananis4, 1Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, 3Specialty Care, Pfizer Inc, Collegeville, PA, 4Specialty Care, Pfizer Inc., Collegeville, PA

    Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
  • Abstract Number: 403 • 2012 ACR/ARHP Annual Meeting

    The Impact of Reaching Low Disease Activity in the First Year On Future Disability and Damage in Patients with Early Rheumatoid Arthritis

    Pooneh Akhavan1, George A. Tomlinson2, Paul R. Fortin3 and Claire Bombardier1, 1Rheumatology, University of Toronto, Toronto, ON, Canada, 2Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, 3Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada

    Background/Purpose: Remission has been proposed as the goal of treatment in patients with early rheumatoid arthritis (RA) by current clinical practice guidelines. Remission is ideal…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology